Results 171 to 180 of about 1,477,881 (298)
Development, anti-proliferative activity, multi-target kinase inhibition against CHK1, PIM1, and CDK-2, and computational insights of new thiazole-based hybrids. [PDF]
Altwaijry NA +6 more
europepmc +1 more source
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela +13 more
wiley +1 more source
A systems approach identifies MERTK as a therapeutic vulnerability in ZFTA-RELA-driven ependymomas. [PDF]
Chan M +10 more
europepmc +1 more source
LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR‐1
J. Lizcano +10 more
semanticscholar +1 more source
ABSTRACT Background Myasthenia gravis (MG) is a rare disorder characterized by fluctuating muscle weakness with potential life‐threatening crises. Timely interventions may be delayed by limited access to care and fragmented documentation. Our objective was to develop predictive algorithms for MG deterioration using multimodal telemedicine data ...
Maike Stein +7 more
wiley +1 more source
Host kinase regulation of Plasmodium vivax dormant and replicating liver stages. [PDF]
Glennon EKK +8 more
europepmc +1 more source
Metabolic Kinases Moonlighting as Protein Kinases.
Zhimin Lu, T. Hunter
semanticscholar +1 more source
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo +9 more
wiley +1 more source
Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability
ABSTRACT Background Myasthenia gravis (MG) is a rare, autoimmune disorder characterized by fluctuating muscle weakness and potential life‐threatening crises. While continuous specialized care is essential, access barriers often delay timely interventions. To address this, we developed MyaLink, a telemedical platform for MG patients.
Maike Stein +13 more
wiley +1 more source
A Novel Tyrosine Kinase Axis in Innate Immune Signaling. [PDF]
Das S +3 more
europepmc +1 more source

